First Turn Management LLC Has $14.43 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

First Turn Management LLC increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 53.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 326,494 shares of the company’s stock after acquiring an additional 113,550 shares during the quarter. Vera Therapeutics comprises 2.3% of First Turn Management LLC’s portfolio, making the stock its 23rd biggest holding. First Turn Management LLC’s holdings in Vera Therapeutics were worth $14,431,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after buying an additional 688 shares in the last quarter. Arizona State Retirement System grew its holdings in Vera Therapeutics by 14.4% in the 2nd quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock valued at $358,000 after buying an additional 1,250 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Vera Therapeutics by 13.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock valued at $425,000 after buying an additional 1,400 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Vera Therapeutics by 30.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after buying an additional 1,737 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Price Performance

VERA opened at $44.81 on Tuesday. Vera Therapeutics, Inc. has a 52-week low of $12.28 and a 52-week high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The business’s fifty day moving average is $42.70 and its 200-day moving average is $39.45.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VERA has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Scotiabank initiated coverage on Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price objective on the stock. Guggenheim upped their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. JPMorgan Chase & Co. upped their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Wedbush increased their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.88.

Insider Buying and Selling

In related news, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. This represents a 0.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total value of $575,366.96. Following the sale, the chief executive officer now owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,398 shares of company stock worth $4,376,163 in the last ninety days. 21.70% of the stock is owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.